Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma

Ahn,Eun  Hyun; Mercado,Gabriela  E.; Laé,Marick; Ladanyi,Marc

doi:10.3892/or.2013.2513

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma

Authors:
- Eun Hyun Ahn
- Gabriela E. Mercado
- Marick Laé
- Marc Ladanyi
View Affiliations

Affiliations: Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Published online on: June 3, 2013 https://doi.org/10.3892/or.2013.2513
Pages: 968-978

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rhabdomyosarcoma (RMS) is a soft tissue sarcoma categorized into two major subtypes: alveolar RMS (ARMS) and embryonal RMS (ERMS). Most ARMS express the PAX3-FOXO1 (P3F) fusion oncoprotein generated by the 2;13 chromosomal translocation. In the present study, the downstream target genes of P3F were identified by analyzing two independent sets of gene expression profiles: primary RMS tumors and RD ERMS cells transduced with inducible P3F constructs. We found 34 potential target genes (27 upregulated and 7 downregulated) that were significantly and differentially expressed between P3F-positive and P3F-negative categories, both in primary RMS tumors and in the inducible P3F cell culture system. Gene ontology analysis of microarray data of the inducible P3F cell culture system employed indicated apoptosis, cell death, development, and signal transduction as overrepresented significant functional categories found in both upregulated and downregulated genes. Therefore, among the 34 potential target genes, the expression of cell death‑related [Gremlin1, cysteine knot superfamily 1, BMP antagonist 1 (GREM1) and death-associated protein kinase 1 (DAPK1)] and development‑related [myogenic differentiation 1 (MYOD1) and hairy/enhancer-of-split related with YRPW motif 1 (HEY1)] genes were further investigated. The differential expression of GREM1, DAPK1, MYOD1 and HEY1 was confirmed in independent tumors and inducible cell culture systems. The expression of GREM1, DAPK1 and MYOD1 were significantly upregulated; HEY1 was significantly downregulated in independent P3F-positive ARMS tumors and transcriptionally active P3F cells, compared to those in ERMS tumors and transcriptionally inactive P3F cells. This study identified target genes of P3F and suggested that four downstream targets (GREM1, DAPK1, MYOD1 and HEY1) can contribute to the biological activities of P3F involved in growth suppression or cell death and myogenic differentiation.

View Figures

View References

1	Linardic CM: PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 270:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
2	Sorensen PH, Lynch JC, Qualman SJ, et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 20:2672–2679. 2002.PubMed/NCBI
3	Stevens MC: Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 6:77–84. 2005. View Article : Google Scholar : PubMed/NCBI
4	Scrable HJ, Witte DP, Lampkin BC and Cavenee WK: Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 329:645–647. 1987. View Article : Google Scholar : PubMed/NCBI
5	Visser M, Sijmons C, Bras J, et al: Allelotype of pediatric rhabdomyosarcoma. Oncogene. 15:1309–1314. 1997. View Article : Google Scholar
6	Davis RJ and Barr FG: Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 94:8047–8051. 1997. View Article : Google Scholar
7	Du S, Lawrence EJ, Strzelecki D, Rajput P, Xia SJ, Gottesman DM and Barr FG: Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma. Int J Cancer. 115:85–92. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kelly KM, Womer RB, Sorensen PHB, Xiong QB and Barr FG: Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol. 15:1831–1836. 1997.PubMed/NCBI
9	Anderson J, Gordon T, McManus A, et al: Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer. 85:831–835. 2001. View Article : Google Scholar : PubMed/NCBI
10	Khan J, Bittner ML, Saal LH, et al: cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA. 96:13264–13269. 1999. View Article : Google Scholar : PubMed/NCBI
11	Wachtel M, Dettling M, Koscielniak E, et al: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;q23) translocation fusing PAX3 to NCOA1. Cancer Res. 64:5539–5545. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wachtel M, Runge T, Leuschner I, et al: Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 24:816–822. 2006. View Article : Google Scholar : PubMed/NCBI
13	Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ and Anderson MJ: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. Cancer Res. 66:6936–6946. 2006. View Article : Google Scholar : PubMed/NCBI
14	De Pittà C, Tombolan L, Albiero G, et al: Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer. 118:2772–2781. 2006.
15	Laé M, Ahn EH, Mercado GE, et al: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FOXO1 fusion-negative embryonal rhabdomyosarcomas. J Pathol. 212:143–151. 2007.PubMed/NCBI
16	Mercado GE, Xia SJ, Zhang C, et al: Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer. 47:510–520. 2008. View Article : Google Scholar
17	Barr FG, Smith LM, Lynch JC, Strzelecki D, Parham DM, Qualman SJ and Breitfeld PP: Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children’s Oncology Group. J Mol Diagn. 8:202–208. 2006.PubMed/NCBI
18	Bennicelli JL, Edwards RH and Barr FG: Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 93:5455–5459. 1996. View Article : Google Scholar : PubMed/NCBI
19	Tomescu O, Xia SJ, Strezlecki D, Bennicelli JL, Ginsberg J, Pawel B and Barr FG: Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest. 84:1060–1070. 2004. View Article : Google Scholar : PubMed/NCBI
20	Xia SJ and Barr FG: Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene. 23:6864–6871. 2004. View Article : Google Scholar : PubMed/NCBI
21	Xia SJ, Rajput P, Strzelecki DM and Barr FG: Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest. 87:318–325. 2007.PubMed/NCBI
22	Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686–1690. 1995. View Article : Google Scholar : PubMed/NCBI
23	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001. View Article : Google Scholar : PubMed/NCBI
24	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
25	Ahn EH and Schroeder JJ: Sphinganine causes early activation of JNK and p38 MAPK and inhibition of AKT in HT-29 human colon cancer cells. Anticancer Res. 26:121–127. 2006.PubMed/NCBI
26	Tonin PN, Scrable H, Shimada H and Cavenee WK: Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 51:5100–5106. 1991.PubMed/NCBI
27	Tapscott SJ, Thayer MJ and Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 259:1450–1453. 1993. View Article : Google Scholar : PubMed/NCBI
28	Ren YX, Finckenstein FG, Abdueva DA, et al: Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68:6587–6597. 2008. View Article : Google Scholar : PubMed/NCBI
29	Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX and Anderson MJ: PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 27:2004–2014. 2008.PubMed/NCBI
30	Sun J, Kamei CN, Layne MD, Jain MK, Liao JK, Lee ME and Chin MT: Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2. J Biol Chem. 276:18591–18596. 2001. View Article : Google Scholar : PubMed/NCBI
31	Epstein JA, Lam P, Jepeal L, Maas RL and Shapiro DN: Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem. 270:11719–11722. 1995. View Article : Google Scholar : PubMed/NCBI
32	Ebauer M, Wachtel M, Niggli FK and Schäfer BW: Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 26:7267–7281. 2007. View Article : Google Scholar : PubMed/NCBI
33	Kikuchi K, Tsuchiya K, Otabe O, et al: Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 365:568–574. 2008. View Article : Google Scholar : PubMed/NCBI
34	Collins MH, Zhao H, Womer RB and Barr FG: Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 37:83–89. 2001. View Article : Google Scholar : PubMed/NCBI
35	Anderson J, Ramsay A, Gould S and Pritchard-Jones K: PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol. 159:1089–1096. 2001. View Article : Google Scholar : PubMed/NCBI
36	Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ III and Schäfer BW: Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA. 93:13164–13169. 1996. View Article : Google Scholar : PubMed/NCBI
37	Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E and Rauscher FJ III: Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res. 60:5803–5814. 2000.PubMed/NCBI
38	Xia SJ, Holder DD, Pawel BR, Zhang C and Barr FG: High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol. 175:2600–2608. 2009. View Article : Google Scholar : PubMed/NCBI
39	Chen B, Athanasiou M, Gu Q and Blair DG: Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun. 295:1135–1141. 2002. View Article : Google Scholar : PubMed/NCBI
40	Bialik S and Kimchi A: DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol. 14:283–294. 2004. View Article : Google Scholar : PubMed/NCBI